Diagnostic Approaches for Chlamydia Trachomatis Infections

Chlamydia trachomatis remains the most prevalent bacterial sexually transmitted infection worldwide, frequently asymptomatic yet a major driver of reproductive morbidity. Accurate and timely diagnosis underpins effective treatment, surveillance and control programmes. Traditional approaches—including cell culture and direct immunofluorescence—have largely been supplanted by molecular methods that combine high sensitivity with rapid turnaround. Nucleic acid amplification tests (NAATs) are now the cornerstone of clinical practice, offering excellent performance on urogenital and extra-genital specimens. Innovations in isothermal amplification, CRISPR-based detection and portable sequencing platforms promise decentralised testing in low-resource settings. Rapid antigen tests have seen incremental improvements, though their sensitivity typically trails molecular assays. Recent studies have also explored serological markers and host-response signatures to complement direct pathogen detection and inform on chronic or past infection. Interdisciplinary advances draw on nanotechnology, microfluidics and point-of-care integration to expand access to testing, particularly in underserved regions, and to facilitate screening among high-risk populations such as adolescents and men who have sex with men. The global significance of improved diagnostics extends beyond individual patient care to enhanced epidemiological surveillance and antimicrobial stewardship.

Research from Nature Portfolio

Recent studies have refined CRISPR-Cas12a-based assays for Chlamydia trachomatis, achieving single-copy sensitivity in under 30 minutes. By coupling isothermal recombinase polymerase amplification with Cas12a collateral cleavage, researchers have attained point-of-care readiness without sacrificing specificity, even on self-collected vaginal swabs. Parallel advances in nanopore sequencing have enabled direct metagenomic identification of C. trachomatis from urine and anorectal specimens. This approach bypasses target amplification and provides genome-wide data, facilitating both diagnosis and strain typing in a single workflow. Further work has demonstrated lab-on-chip platforms integrating loop-mediated isothermal amplification (LAMP) within a microfluidic cartridge, delivering results in less than an hour with minimal hands-on time. Such platforms exhibit resilience to supply-chain disruptions and have been piloted in community clinics with promising uptake, indicating a shift towards decentralised molecular testing.

Diagnostic Approaches for Chlamydia Trachomatis Infections publication trend

The graph below shows the total number of articles in diagnostic approaches for chlamydia trachomatis infections across all publications each year (not limited to Nature Index journals).

Technical terms

Nucleic acid amplification test (NAAT): A molecular method that detects and amplifies pathogen-specific genetic material, providing high sensitivity and specificity.

Isothermal amplification: Techniques such as LAMP or recombinase polymerase amplification that amplify nucleic acids at a constant temperature, obviating thermocyclers.

CRISPR–Cas12a: A class II CRISPR effector protein that, upon target recognition, cleaves nearby single-stranded DNA reporters, enabling rapid molecular detection.

Nanopore sequencing: A real-time sequencing technology that threads nucleic acids through protein nanopores, allowing direct pathogen identification and genotyping.

Serological marker: An antibody or antigen detected in blood that indicates current or past infection.

References

1. Combination of Individual Tests to Improve Diagnostic Accuracy in Chlamydia trachomatis Detection. Medicina (2025).